Anti-tumour necrosis factor alpha therapy: can we afford it?
Symmons
D P M
DP
ARC Epidemiology Unit, Stopford Building, University of Manchester, Oxford Road, Manchester M13 9PT, UK. deborah.symmons@man.ac.uk
D000068879:Adalimumab; D000911:Antibodies, Monoclonal / Q000191:economics* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000191:economics*; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D006801:Humans; D018803:Models, Economic; D018579:Patient Selection; D011640:Public Policy; D013222:State Medicine / Q000191:economics; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology*; D006113:United Kingdom
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab